Julián Panés
Appearances
- DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 9, 2023BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
Presenter
Brigham and Women's HospitalSpeakers
Western UniversityUniversity of PennsylvaniaUniversity of Chicago Division of the Biological Sciences - DateMay 20, 2024The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
Brigham and Women's HospitalWestern UniversityUniversity of Pennsylvania - DateMay 20, 2024BACKGROUND: Complex perianal fistulas are a serious complication in patients with Crohn’s disease (CD)…
Speakers
Presenter
Mayo Clinic, Rochester - DateMay 21, 2024BACKGROUND: Darvadstrocel (DVS), a suspension of expanded allogeneic adipose-derived mesenchymal stem cells, is approved for the treatment of complex Crohn’s perianal fistulas (CPF)…
